Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Kubin ruling extends KSR logic to biotech (Managing IP) (Technology Transfer Tactics) (Patent Docs) (Patent Docs)

Evista (Raloxifene) Xigris (Drotrecogin alfa) – Court finds Ariad patent claims in suit v. Eli Lilly invalid (Patent Baristas), (Law 360) (Patent Docs)

Blockbusters and other strategies (IP Think Tank)

AU – TRIPS, Pharmaceuticals and Manufacture for Export – IP Think Tank Podcast (IP Think Tank)

Germany: Open fight on biotechnology, patents, and CIIs (IP Jur)

US – It’s not an invention if you use conventional techniques to make it (Patent Baristas)

US – Debate on creating a regulatory pathway for approval of follow-on biologics (FOB) (Patent Baristas)

US – Federal Trade Commission (FTC) loses venue fight in reverse payment deal suit (Law 360)

US – Kubin ruling extends KSR logic to biotech (Managing IP) (Technology Transfer Tactics) (Patent Docs) (Patent Docs)

US District Court rules on ‘case or controversy’ and declaratory judgments in ANDA Hatch Waxman litigation (FDA Law Blog)

US ITC decides imported Chinese sucralose does not infringe Tate & Lyle patents (IAM)

Clarinex (Desloratadine) – Mylan and Schering settle patent litigation (Law 360)

Detrol (Tolterodine) – Pfizer’s Detrol patent still enforceable (Law 360)

Effexor (Venlafaxine) Wyeth targets Zydus in new Effexor XR patent suit (Law 360)

Evista (Raloxifene) Xigris (Drotrecogin alfa) – Court finds Ariad patent claims in suit v. Eli Lilly invalid (Patent Baristas), (Law 360) (Patent Docs)

Gleevec / Glivec (Imatinib) – Novartis alpha crystalline form patent invalidated at pre – grant opposition (PatentCircle)

Levaquin (Levofloxacin) – Daiichi Sankyo Co. Ltd. sues 11 generics companies over Levaquin patents (Law 360)

Lexapro (Escitalopram) – Netherlands District court invalidates Lundbeck’s patent EP ‘066 (IPKat)

Lexapro (Escitalopram) – Baldwin’s rules explained (The SPC Blog)

Lexapro (Escitalopram) – federal district Judge agrees to determine whether Forest Laboratories destroyed key documents (Law 360)

Pegasys (PEG interferon alfa 2a) – Roche wins post grant opposition against Wockhardt (PatentCircle)

Tamiflu (Oseltamivir) – Cipla invalidates Gilead patent at pregrant opposition (PatentCircle)

Vanos (Fluocinonide) – Medicis and Perrigo settle patent dispute (Law 360)

Vyvanse (Lisdexamfetamine) – lawsuit over withdrawal of New Chemical Entity Exclusivity put on hold pending public comment to FDA (FDA Law Blog)

Xeloda (Capecitabine) – Hoffmann-La Roche Inc. sues Mylan Pharmaceuticals Inc. over generic Xeloda ANDA (Law 360)

Xeloda (Capecitabine) – Mylan confirms first to file patent challenge (Smartbrief)